ArticleMolecular medicine reports2026
Glucose‑driven TRIB3 enhances the tumorigenic potential of colon cancer via the PI3K/AKT pathway.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes, characterized by chronic hyperglycemia, is closely associated with worse outcomes in patients with colorectal cancer (CRC). However, the mechanism underlying the influence of high glucose levels on CRC prognosis has not yet been fully elucidated. Tribbles 3 (TRIB3) protein, a unique pseudokinase, has been implicated as an intermediary between metabolism and oncogenesis. The present study aimed to elucidate whether TRIB3 is modulated by elevated glucose levels in CRC and contributes to the malignant behavior of diabetic CRC tumors. TRIB3 expression was detected using immunohistochemistry in colon cancer tissues from patients with and without diabetes. Following the knockdown of TRIB3 by short hairpin RNA, colon cancer cell proliferation and migration were assessed using Cell Counting Kit‑8 and Transwell assays. Additionally, changes in the expression of related genes were detected using reverse transcription‑quantitative PCR, western blotting and immunofluorescence staining. The present study detected significant upregulation of TRIB3 in diabetic CRC. In addition, the findings indicated that TRIB3 may promote epithelial‑mesenchymal transition (EMT) by activating the PI3K/AKT signaling pathway, thereby enhancing the malignant characteristics of CRC. By contrast, TRIB3 knockdown in CRC cells mitigated glucose‑induced proliferation, invasiveness and EMT progression. In conclusion, TRIB3 may be modulated by increased glucose levels, subsequently contributing to the malignancy of tumor cells in diabetic CRC by modifying EMT status. These findings underscore the potential of TRIB3 as a therapeutic target for effective management of patients with diabetic and CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.